以下文章来源于侃见财经 ，作者侃见财经 侃见财经 . 看见不一样的财经！ 导语：创新药的BD阶段已过，业绩兑现将成为未来药企的主流方向。 2月27日，一则亏损的业绩快报，将"创新药明星股"百利天恒推向了风口浪尖。 2024年，百利天恒通过iza-bren的知识产权授权，获得了8亿美元的不可撤销、不可抵扣首付 款，这让其2024年业绩实现扭亏为盈。 但值得注意的是，2025年iza-bren知识产权授权的里程碑付款骤降至2.5亿美元，这也导致公司 业绩出现了较大幅度波动。 实际上，尽管市场对百利天恒"成为世界级MNC"寄予厚望，但从目前来看，这条道路并不平坦。 一方面，创新药研发本就是如同无底洞一般的"金钱游戏"。创始人朱义曾提到，要支撑公司成为 入门级MNC，至少需要10亿美元的资金储备。从现金储备角度来看，截至2025年三季度末，百 利天恒货币资金为60.86亿元，虽然资金体量不小，但对于创新药研发而言，资金压力依旧存 在。另一方面，随着竞争加剧，辉瑞、罗氏等医药巨头开始主动收缩战线，头部跨国药企相关支 出若出现缩减，对依赖BD预期的药企而言，并非好事。 从资本市场角度来看，BD风口已过，市场对创新药企业开 ...

Core Insights - Baili Tianheng, a leading innovative pharmaceutical company, has submitted its prospectus to the Hong Kong Stock Exchange (HKEX) after completing the largest A-share financing in the healthcare sector since the implementation of the comprehensive registration system [1][2] - The company's stock price has surged significantly, reaching a maximum of 414.02 CNY per share by September 8, 2025, representing a cumulative increase of over 15 times since its initial public offering [1][8] - The recent A-share financing raised a total of 3.764 billion CNY, with participation from top fund managers, indicating strong institutional interest [1][8][13] Financing and Market Position - The recent A-share financing is the largest in the healthcare sector since the registration system was implemented, marking a significant step in Baili Tianheng's global expansion strategy [13] - The funds raised will be allocated entirely to innovative drug research and development, particularly for the ADC and multi-specific antibody platforms [13] - Baili Tianheng has become a star stock among institutional investors, with significant participation from well-known fund managers [8][13] Clinical Developments - Baili Tianheng's core product, BL-B01D1, has shown promising clinical results, achieving a 100% objective response rate in a recent Phase II study for EGFR-mutant non-small cell lung cancer [15][16] - The company has also received breakthrough therapy designations for multiple indications, including various cancers, which will expedite the drug's development and review process [17][18] - The company has made significant progress in the ARC field, receiving approval for clinical trials of its first-in-class drug, BL-ARC001 [22] Leadership and Vision - The company's growth trajectory is closely linked to its founder, Zhu Yi, who aims to transform Baili Tianheng into an entry-level multinational corporation (MNC) within five years [23][26] - Zhu Yi's background in academia and his transition from generic drugs to innovative pharmaceuticals reflect a strategic vision aligned with the evolving pharmaceutical landscape in China [25][26] - The ambition to create a super blockbuster drug and collaborate with MNCs is central to the company's future strategy [26]

Core Insights - The article discusses the rise of Baili Tianheng, a Chengdu-based biopharmaceutical company, and its founder Zhu Yi, who has recently been labeled as "Sichuan's richest man" due to the company's soaring market value. Zhu Yi emphasizes that this title is merely "paper wealth" and expresses more pressure than honor [1]. Group 1: New Drug Development - Baili Tianheng's core product, iza-bren (BL-B01D1), is a first-in-class dual antibody ADC that has achieved a 100% objective response rate (ORR) in clinical trials for treating EGFR-mutant non-small cell lung cancer [2][6]. - The company has submitted a listing application to the Chinese National Medical Products Administration (NMPA) and expects approval around June 2026, with a later launch in the U.S. anticipated by 2029 [6][10]. - The drug has been in development for over 10 years, with the research starting in 2014, highlighting the long timeline required for original innovation in the pharmaceutical industry [6][10]. Group 2: Investment and Expansion Plans - Baili Tianheng plans to invest an additional 2 billion yuan (approximately 0.3 billion USD) in a new facility in Chengdu Medical City, which will include a large workshop, transformation center, and laboratory [8][10]. - The new facility is expected to support the nationwide and partial global supply of iza-bren, with projected annual sales exceeding 10 billion yuan (approximately 1.5 billion USD) once production reaches 70% capacity [10]. Group 3: Future Aspirations - Zhu Yi aims for Baili Tianheng to become a leading multinational corporation (MNC) in oncology treatment within five years, with global commercialization expected by 2029 [11]. - The company is focusing on maintaining global leadership in research and development, clinical development capabilities, and supply chain management as key indicators of becoming an entry-level MNC [11]. Group 4: Chengdu's Biopharmaceutical Environment - Chengdu is seen as an advantageous location for biopharmaceutical development due to its improving business environment and the stability of its research teams, which is crucial for successful drug development [15][17]. - Zhu Yi notes that Chengdu's ability to attract high-end talent has improved, and he suggests further enhancements in policies related to international schools and healthcare for expatriates to boost talent attraction [16].